This year (FY 05) profit will be above $500m with a oneoff of $200m capital gain. This is a far cry from $70mil, 2 years ago.
With FDA approval early next year for HPV then a oneoff bonus payment from Merck comes in.
Are we looking at a cheap (PE) company as this one-off have not been factored in?
After all once HPV vaccine hits the market an extra 150-200m annual addition on profit is on the card as well...
buy buy buy buy buy - , page-2
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$301.66 |
Change
1.790(0.60%) |
Mkt cap ! $146.0B | |||
| Open | High | Low | Value | Volume |
| $301.73 | $302.12 | $299.87 | $209.3M | 694.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1810 | $301.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $301.75 | 780 | 2 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| CSL (ASX) Chart |